IN-SILICO STUDY: MYRICETIN FROM THE STEM BARK OF SYZYGIUM CUMINI INHIBITS THE GROWTH OF NON-SMALL CELL LUNG CANCER CELLS THROUGH THE EGFR PATHWAY
AbstractAround the world, cancer frequently leads to death. Lung cancer is the primary cause of cancer-related deaths globally. Through in-silico analysis, this study sought to assess the anticancer effectiveness of myricetin on human lung cancer cells. The study’s goal is to assess how well myricetin adheres to the Lipinski rule of 5. To evaluate the ADMET properties (Absorption, Distribution, Metabolism, Excretion, Toxicity) for myricetin. To predict the target-ligand interaction. The results from these studies supported that the myricetin follows the Lipinski rule of 5 and ADMET properties. Myricetin has a better H bond interaction. The results of the in-silico analysis used in this work serve as encouraging evidence for the prediction of the mechanism by which myricetin acts to cause apoptosis via the EGFR pathway. The results from the molecular docking study suggested that myricetin inhibited critical tumorigenic effects through apoptosis. Thus myricetin could be further explored as a promising chemotherapeutic agent in lung cancer treatment.
Article Information
12
1384-1390
739 KB
497
English
IJPSR
M. Viji, S. Aishwariya, C. Ireen, S. Hinduja, S. Indu, P. Vijayalakshmi and M. Rajalakshmi *
DBT-BIF Centre, Holy Cross College (Autonomous), Tiruchirappalli, Tamil Nadu, India.
rajalakshmi@hcctrichy.ac.in.
04 October 2023
12 January 2024
04 April 2024
10.13040/IJPSR.0975-8232.15(5).1384-90
01 May 2024
Download